NASDAQ · GMAB

Genmab A/S

$28.87 -$0.30 (-1.03%) 1D After hours
Session Pulse Overnight session 2 mentions on Tue · 2 bullish / 0 bearish tags No new SEC filings since Mon close Full pulse →
Charting by TradingView

Key Metrics

$17.91B
Market cap
18.60×
P/E · TTM
$3.72B
Revenue · TTM
$963.00M
Net income
EPS · TTM $1.57
Dividend yield —
Free cash flow —
Beta · 1Y 0.75
EBITDA · TTM —
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 2
    From its Jan 29 high, the share price fell 28%.

    Peak close $33.35 on Jan 29; trough close $23.85 on Jun 2. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -28%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$17.91B
Enterprise value—
Shares outstanding613.9M
52-wk range$21.00 – $35.43
Avg volume · 20D900.5K
Net cash —
Book value / share—
ExchangeNASDAQ
About Genmab A/S
IPO dateOct 5, 2010
Employees3088

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E18.60
P/S4.81
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—

Profitability

Gross —
Operating —
Net 25.9%
FCF —
ROE / ROIC — · —

Financial Health

Current ratio—
Quick ratio—
Debt / equity—
Debt / EBITDA —
Net cash —
Working capital—

Cash Flow · TTM

Operating CF —
Capex —
Free cash flow —
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

—
Insufficient balance-sheet inputs

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2025-06-30 · computed by TickerWolf from SEC filings